#1 Clinical Trials Search in Europe

Mesenchymal Cells

This article examines ongoing clinical trials investigating the use of mesenchymal cells as potential treatments for various medical conditions. The trials focus on bronchopulmonary dysplasia in premature infants, degenerative disc disease in adults with chronic low back pain, and other respiratory issues. Researchers are evaluating the safety and efficacy of administering mesenchymal cells derived from sources like umbilical cord tissue and bone marrow to address these challenging health problems.

Table of Contents

What are Mesenchymal Cells?

Mesenchymal cells, also known as mesenchymal stem cells (MSCs), are a type of multipotent stem cell that can develop into various cell types in the body[1]. These cells have gained significant attention in medical research due to their potential therapeutic applications in treating various conditions.

Potential Applications

Mesenchymal cells are being studied for their potential to treat a wide range of medical conditions, including:

  • Bronchopulmonary dysplasia (BPD) in preterm infants
  • Degenerative disc disease (DDD) causing chronic low back pain
  • Other respiratory and musculoskeletal disorders

Bronchopulmonary Dysplasia in Preterm Infants

One of the most promising applications of mesenchymal cells is in the treatment of bronchopulmonary dysplasia (BPD) in extremely preterm newborns[1]. BPD is a serious lung condition that can affect premature infants, particularly those born before 28 weeks of gestation.

Researchers are investigating the use of mesenchymal cells derived from various sources, including:

  • Umbilical cord mesenchymal cells
  • Allogeneic (donor-derived) mesenchymal cells

These cells are being studied for their potential to:

  • Reduce inflammation in the lungs
  • Promote lung development
  • Prevent or reduce the severity of BPD

Degenerative Disc Disease

Another area of research focuses on using mesenchymal cells to treat degenerative disc disease (DDD), a condition that can cause chronic low back pain[2]. DDD occurs when the intervertebral discs in the spine deteriorate, leading to pain and reduced mobility.

Researchers are exploring the potential of mesenchymal cells to:

  • Reduce pain associated with DDD
  • Improve disc fluid content and overall disc health
  • Enhance function and quality of life for patients with chronic low back pain

Administration Methods

The method of administering mesenchymal cells varies depending on the condition being treated:

  • For BPD in preterm infants, cells may be administered through intratracheal (directly into the windpipe) or intravenous (into a vein) routes[1][3].
  • For degenerative disc disease, cells are typically administered through intradiscal injection (directly into the affected disc)[2].

Safety and Efficacy

Current clinical trials are primarily focused on establishing the safety and efficacy of mesenchymal cell treatments. Researchers are monitoring for potential side effects and evaluating the effectiveness of these treatments in improving patient outcomes[1][2][3].

Some of the key aspects being studied include:

  • Short-term and long-term safety of mesenchymal cell administration
  • Optimal dosing and frequency of treatments
  • Effectiveness in reducing symptoms and improving overall health
  • Potential impact on long-term development and quality of life

Ongoing Research

Multiple clinical trials are currently underway to further investigate the potential of mesenchymal cells in treating various conditions. These studies aim to provide more comprehensive data on the safety and efficacy of these treatments, which could potentially lead to new therapeutic options for patients in the future[1][2][3].

It’s important to note that while the initial results are promising, mesenchymal cell treatments are still considered experimental. More research is needed before these therapies can be widely adopted in clinical practice.

Aspect Bronchopulmonary Dysplasia Trial Degenerative Disc Disease Trial Preterm Infants BPD Trial
Cell Type Allogeneic umbilical mesenchymal cells-derived extracellular vesicles Allogeneic bone marrow stromal mesenchymal cells Expanded allogeneic fetal umbilical cord stem mesenchymal cells
Administration Route Intratracheal Intradiscal Intravenous
Primary Objective Assess safety and efficacy in preventing BPD Evaluate pain reduction and disc fluid content improvement Evaluate safety and feasibility of repeated infusions
Patient Population Extremely preterm newborns Adults with chronic low back pain due to DDD Preterm infants ≤28 weeks gestational age and ≤1250g weight
Follow-up Duration Up to 2 years corrected age Up to 24 months (60 months in Germany) Up to 24 months of corrected age

FAQ

  • What are mesenchymal cells? Mesenchymal cells are a type of stem cell that can develop into different types of tissues like bone, cartilage, and fat. In these trials, they are being studied for their potential to repair and regenerate damaged tissues in various parts of the body.
  • How are mesenchymal cells administered in these trials? The administration method varies depending on the condition being treated. For bronchopulmonary dysplasia, cells are given through intravenous infusion. In the degenerative disc disease trial, cells are injected directly into the affected disc. For other respiratory issues, intratracheal administration is being studied.
  • What conditions are being targeted in these mesenchymal cell trials? The trials are focusing on bronchopulmonary dysplasia in premature infants, degenerative disc disease causing chronic low back pain in adults, and other respiratory conditions in preterm newborns.
  • What are the main goals of these clinical trials? The primary goals are to assess the safety and efficacy of mesenchymal cell treatments. Researchers are looking at factors like reduction in pain, improvement in lung function, changes in disc fluid content, and overall health outcomes for patients receiving the treatments.
  • How long do these clinical trials last? The duration varies by trial. Some follow patients for up to 24 months after treatment, while others have longer follow-up periods of up to 5 years to assess long-term safety and efficacy.

Ongoing Clinical Trials on Mesenchymal Cells

  • Safety Study of Mesenchymal Cells for Preterm Infants with Bronchopulmonary Dysplasia

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Bronchopulmonary dysplasia (BPD): A chronic lung condition that affects premature infants, characterized by abnormal development of lung tissue and often requiring prolonged oxygen support.
  • Degenerative disc disease (DDD): A condition where the discs between vertebrae in the spine break down, causing pain and decreased mobility.
  • Extracellular vesicles: Small structures released by cells that can carry various molecules and play a role in cell-to-cell communication.
  • Intratracheal administration: A method of delivering medication directly into the trachea (windpipe).
  • Allogeneic: Referring to cells or tissues that are genetically different but from the same species, often used in transplants or cell therapies.
  • Visual Analog Scale (VAS): A measurement tool used to assess pain intensity, typically using a scale from 0 to 100.
  • Oswestry Disability Index (ODI): A questionnaire used to measure the degree of disability and quality of life in a person with low back pain.
  • Magnetic Resonance Imaging (MRI): A medical imaging technique that uses magnetic fields and radio waves to create detailed images of organs and tissues in the body.
  • Postmenstrual age (PMA): The time elapsed between the first day of the last menstrual period and birth (gestational age) plus the time elapsed after birth (chronological age).
  • Pfirrmann's score: A grading system used to assess the degree of lumbar disc degeneration on MRI images.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effect-of-exob-001-in-preventing-bronchopulmonary-dysplasia-in-extremely-preterm-newborns/
  2. http://clinicaltrials.eu/trial/study-on-msv-as-for-chronic-low-back-pain-in-patients-with-degenerative-disc-disease-unresponsive-to-conventional-therapy/
  3. http://clinicaltrials.eu/trial/safety-study-of-mesenchymal-cells-for-preterm-infants-with-bronchopulmonary-dysplasia/